Rani Therapeutics Holdings Inc (RANI)

Currency in USD
0.53
0.00(0.00%)
Closed·
0.530.00(0.00%)
·
RANI Scorecard
Full Analysis
2 analysts have revised their earnings upwards for the upcoming period
RANI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.520.57
52 wk Range
0.393.75
Key Statistics
Prev. Close
0.53
Open
0.54
Day's Range
0.52-0.57
52 wk Range
0.39-3.75
Volume
904.15K
Average Volume (3m)
1.92M
1-Year Change
-80.37%
Book Value / Share
-0.14
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RANI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
8.75
Upside
+1,550.94%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell

Rani Therapeutics Holdings Inc Company Profile

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Compare RANI to Peers and Sector

Metrics to compare
RANI
Peers
Sector
Relationship
P/E Ratio
−0.9x−3.1x−0.5x
PEG Ratio
−0.040.010.00
Price/Book
−4.6x0.8x2.6x
Price / LTM Sales
21.2x1.6x3.3x
Upside (Analyst Target)
-199.5%40.3%
Fair Value Upside
Unlock0.0%4.7%Unlock

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 8.75
(+1,550.94% Upside)

Earnings

Latest Release
Aug 07, 2025
EPS / Forecast
-0.18 / -0.29
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

RANI Income Statement

People Also Watch

2.56
INMB
+5.79%
20.40
SRPT
+8.51%
5.09
REPL
-3.05%
0.536
WINT
+3.47%

FAQ

What Stock Exchange Does Rani Therapeutics Holdings Trade On?

Rani Therapeutics Holdings is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Rani Therapeutics Holdings?

The stock symbol for Rani Therapeutics Holdings is "RANI."

What Is the Rani Therapeutics Holdings Market Cap?

As of today, Rani Therapeutics Holdings market cap is 25.29M.

What Is Rani Therapeutics Holdings's Earnings Per Share (TTM)?

The Rani Therapeutics Holdings EPS (TTM) is -0.90.

When Is the Next Rani Therapeutics Holdings Earnings Date?

Rani Therapeutics Holdings will release its next earnings report on 11 Nov 2025.

From a Technical Analysis Perspective, Is RANI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Rani Therapeutics Holdings Stock Split?

Rani Therapeutics Holdings has split 0 times.

How Many Employees Does Rani Therapeutics Holdings Have?

Rani Therapeutics Holdings has 106 employees.

What is the current trading status of Rani Therapeutics Holdings (RANI)?

As of 14 Aug 2025, Rani Therapeutics Holdings (RANI) is trading at a price of 0.53, with a previous close of 0.53. The stock has fluctuated within a day range of 0.52 to 0.57, while its 52-week range spans from 0.39 to 3.75.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.